Adage Capital Partners Gp, L.L.C. Myovant Sciences Ltd. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$6.55 - $14.76 $3.28 Million - $7.38 Million	-500,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $2.1 Million - $9.61 Million	500,000 New	500,000 $7.76 Million
Q2 2019 Aug 14, 2019	SELL	$8.69 - $25.0 $3.69 Million - $10.6 Million	-425,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$16.83 - $24.45 $5.05 Million - $7.34 Million	-300,000 Reduced 41.38%	425,000 $10.1 Million
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $483,249 - $669,500	25,000 Added 3.57%	725,000 $19.2 Million
Q2 2018 Aug 14, 2018	SELL	$19.2 - $25.14 $3.26 Million - $4.27 Million	-170,000 Reduced 19.54%	700,000 $16 Million
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $8.64 Million - $13.5 Million	870,000	870,000 $13.5 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.